Alnylam drops revusiran development on risk-benefit issues

6 October 2016

US RNAi therapeutics company Alnylam Pharmaceuticals (Nasdaq: ALNY) has decided to halt dosing in the ENDEAVOUR Phase III study on the recommendation of the Data Monitoring Committee (DMC).

As a result, the company will discontinue development of revusiran, an investigational RNA interference (RNAi) therapeutic that was being studied for the treatment of hereditary ATTR amyloidosis with cardiomyopathy (hATTR-CM). Alnylam’s shares plunged 43% to $40.75 in after-hours trading on Wednesday following the announcement.

Following recent reports in the Phase II OLE study of new onset or worsening peripheral neuropathy, the ENDEAVOUR DMC assembled at the company’s request to review these reports and ENDEAVOUR data on an unblinded basis. The DMC did not find conclusive evidence for a drug-related neuropathy signal in the ENDEAVOUR trial, but informed the company that the benefit-risk profile for revusiran no longer supported continued dosing. The company subsequently reviewed unblinded ENDEAVOUR data which revealed an imbalance of mortality in the revusiran arm as compared to placebo.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK